177 related articles for article (PubMed ID: 17124248)
1. Adalimumab: a new modality for Behçet's disease?
van Laar JA; Missotten T; van Daele PL; Jamnitski A; Baarsma GS; van Hagen PM
Ann Rheum Dis; 2007 Apr; 66(4):565-6. PubMed ID: 17124248
[No Abstract] [Full Text] [Related]
2. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
[No Abstract] [Full Text] [Related]
3. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.
Belzunegui J; López L; Paniagua I; Intxausti JJ; Maíz O
Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S133-4. PubMed ID: 19026138
[No Abstract] [Full Text] [Related]
4. Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.
Olivieri I; D' Angelo S; Padula A; Leccese P; Mennillo GA
Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S112. PubMed ID: 19796550
[No Abstract] [Full Text] [Related]
5. Adalimumab for sight-threatening uveitis in Behçet's disease.
Mushtaq B; Saeed T; Situnayake RD; Murray PI
Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
[TBL] [Abstract][Full Text] [Related]
6. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy.
Ariyachaipanich A; Berkelhammer C; Nicola H
Inflamm Bowel Dis; 2009 Dec; 15(12):1769-71. PubMed ID: 19177427
[No Abstract] [Full Text] [Related]
7. Successful treatment of genital ulcers with infliximab in Behcet's disease.
Haugeberg G; Velken M; Johnsen V
Ann Rheum Dis; 2004 Jun; 63(6):744-5. PubMed ID: 15140785
[No Abstract] [Full Text] [Related]
8. Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab.
Sànchez-Cano D; Callejas-Rubio JL; Ortego-Centeno N; Ruiz-Villaverde R
Clin Exp Rheumatol; 2006; 24(5 Suppl 42):S128. PubMed ID: 17067448
[No Abstract] [Full Text] [Related]
9. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
Sfikakis PP; Markomichelakis N; Alpsoy E; Assaad-Khalil S; Bodaghi B; Gul A; Ohno S; Pipitone N; Schirmer M; Stanford M; Wechsler B; Zouboulis C; Kaklamanis P; Yazici H
Rheumatology (Oxford); 2007 May; 46(5):736-41. PubMed ID: 17403712
[No Abstract] [Full Text] [Related]
10. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis.
Takase K; Ohno S; Ideguchi H; Uchio E; Takeno M; Ishigatsubo Y
Rheumatol Int; 2011 Feb; 31(2):243-5. PubMed ID: 19816689
[TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
12. Effect of infliximab on refractory uveitis in Behcet's disease.
Sayarlioglu M; Cinal A; Topcu N; Demirok A
Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
[No Abstract] [Full Text] [Related]
13. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN.
Kotter I; Deuter C; Stubiger N; Zierhut M
J Rheumatol; 2005 Aug; 32(8):1633; author reply 1634. PubMed ID: 16078350
[No Abstract] [Full Text] [Related]
14. Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab.
Atzeni F; Leccese P; D'Angelo S; Sarzi-Puttini P; Olivieri I
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S94. PubMed ID: 20868581
[No Abstract] [Full Text] [Related]
15. Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.
Fujikawa K; Aratake K; Kawakami A; Aramaki T; Iwanaga N; Izumi Y; Arima K; Kamachi M; Tamai M; Huang M; Nakamura H; Nishiura Y; Origuchi T; Ida H; Eguchi K
Ann Rheum Dis; 2007 Jan; 66(1):136-7. PubMed ID: 17178762
[No Abstract] [Full Text] [Related]
16. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
Park J; Cheon JH
Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of adalimumab in Behçet's disease. Description of 6 cases].
Calvo Catalá J; Campos Fernández C; Rueda Cid A; González-Cruz Cervellera MI; Baixauli Rubio A; Pastor Cubillo MD
Reumatol Clin; 2011; 7(4):258-61. PubMed ID: 21794828
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
[No Abstract] [Full Text] [Related]
19. [Treatment of Behçet's disease with adalimumab].
Callejas-Rubio JL; Sánchez-Cano D; Ríos-Férnandez R; Ortego-Centeno N
Med Clin (Barc); 2008 Oct; 131(11):438-9. PubMed ID: 18928730
[No Abstract] [Full Text] [Related]
20. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy.
Goossens PH; Verburg RJ; Breedveld FC
Ann Rheum Dis; 2001 Jun; 60(6):637. PubMed ID: 11350856
[No Abstract] [Full Text] [Related]
[Next] [New Search]
